XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($)
Total
Common Stock
Additional Paid-In Capital
Treasury Stock
Accumulated Other Comprehensive Loss
Accumulated Deficit
Cumulative Effect, Period of Adoption, Adjustment
Cumulative Effect, Period of Adoption, Adjustment
Additional Paid-In Capital
Cumulative Effect, Period of Adoption, Adjustment
Accumulated Deficit
Beginning balance (in shares) at Jan. 31, 2021   60,898,451              
Beginning balance at Jan. 31, 2021 $ (5,033,000) $ 61,000 $ 932,332,000 $ (1,319,000) $ (704,000) $ (935,403,000) $ (256,746,000) $ (309,381,000) $ 52,635,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock option exercises (in shares)   483,787              
Stock option exercises 3,540,000 $ 1,000 3,539,000            
Vesting of early exercised stock options 10,000   10,000            
Vesting of restricted stock units (in shares)   341,939              
Vesting of restricted stock units 0                
Stock-based compensation 50,914,000   50,914,000            
Conversion of 2024 convertible senior notes (in shares)   372,096              
Conversion of convertible senior notes 2,999,000   2,999,000            
Unrealized income (loss) on available-for-sale securities 34,000       34,000        
Foreign currency translation adjustment (90,000)       (90,000)        
Net loss (63,992,000)         (63,992,000)      
Ending balance (in shares) at Apr. 30, 2021   62,096,273              
Ending balance at Apr. 30, 2021 (268,364,000) $ 62,000 680,413,000 (1,319,000) (760,000) (946,760,000)      
Beginning balance (in shares) at Jan. 31, 2021   60,898,451              
Beginning balance at Jan. 31, 2021 (5,033,000) $ 61,000 932,332,000 (1,319,000) (704,000) (935,403,000) $ (256,746,000) $ (309,381,000) $ 52,635,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock option exercises (in shares)   219,696              
Stock option exercises 1,848,000   1,848,000            
Vesting of restricted stock units (in shares)   366,226              
Vesting of restricted stock units 1,000 $ 1,000              
Stock-based compensation 69,620,000   69,620,000            
Conversion of 2024 convertible senior notes (in shares)   202              
Conversion of convertible senior notes 17,000   17,000            
Unrealized income (loss) on available-for-sale securities (350,000)                
Foreign currency translation adjustment (238,000)                
Net loss (222,418,000)                
Ending balance (in shares) at Oct. 31, 2021   66,716,713              
Ending balance at Oct. 31, 2021 662,905,000 $ 67,000 1,770,635,000 (1,319,000) (1,292,000) (1,105,186,000)      
Beginning balance (in shares) at Apr. 30, 2021   62,096,273              
Beginning balance at Apr. 30, 2021 (268,364,000) $ 62,000 680,413,000 (1,319,000) (760,000) (946,760,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock option exercises (in shares)   282,519              
Stock option exercises 2,206,000   2,206,000            
Vesting of restricted stock units (in shares)   362,342              
Vesting of restricted stock units 0                
Stock-based compensation 57,705,000   57,705,000            
Conversion of 2024 convertible senior notes (in shares)   844,194              
Conversion of convertible senior notes 56,683,000 $ 1,000 56,682,000            
Issuance of common stock, net of issuance costs (in shares)   2,500,000              
Issuance of common stock, net of issuance costs 889,184,000 $ 3,000 889,181,000            
Issuance of common stock under the Employee Stock Purchase Plan (in shares)   45,261              
Issuance of common stock under the Employee Stock Purchase Plan 12,963,000   12,963,000            
Unrealized income (loss) on available-for-sale securities (86,000)       (86,000)        
Foreign currency translation adjustment 566,000       566,000        
Net loss (77,133,000)         (77,133,000)      
Ending balance (in shares) at Jul. 31, 2021   66,130,589              
Ending balance at Jul. 31, 2021 673,724,000 $ 66,000 1,699,150,000 (1,319,000) (280,000) (1,023,893,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Unrealized income (loss) on available-for-sale securities (298,000)       (298,000)        
Foreign currency translation adjustment (714,000)       (714,000)        
Net loss (81,293,000)         (81,293,000)      
Ending balance (in shares) at Oct. 31, 2021   66,716,713              
Ending balance at Oct. 31, 2021 $ 662,905,000 $ 67,000 1,770,635,000 (1,319,000) (1,292,000) (1,105,186,000)      
Beginning balance (in shares) at Jan. 31, 2022 67,444,360 67,444,360              
Beginning balance at Jan. 31, 2022 $ 666,700,000 $ 67,000 1,860,514,000 (1,319,000) (2,928,000) (1,189,634,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock option exercises (in shares)   235,517              
Stock option exercises 1,656,000   1,656,000            
Vesting of restricted stock units (in shares)   381,178              
Vesting of restricted stock units 1,000 $ 1,000              
Stock-based compensation 83,566,000   83,566,000            
Conversion of 2024 convertible senior notes (in shares)   8              
Conversion of convertible senior notes 1,000   1,000            
Unrealized income (loss) on available-for-sale securities (2,364,000)       (2,364,000)        
Foreign currency translation adjustment 613,000       613,000        
Net loss (77,294,000)         (77,294,000)      
Ending balance (in shares) at Apr. 30, 2022   68,061,063              
Ending balance at Apr. 30, 2022 $ 672,879,000 $ 68,000 1,945,737,000 (1,319,000) (4,679,000) (1,266,928,000)      
Beginning balance (in shares) at Jan. 31, 2022 67,444,360 67,444,360              
Beginning balance at Jan. 31, 2022 $ 666,700,000 $ 67,000 1,860,514,000 (1,319,000) (2,928,000) (1,189,634,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock option exercises (in shares) 598,546                
Unrealized income (loss) on available-for-sale securities $ (62,000)                
Foreign currency translation adjustment (801,000)                
Net loss $ (281,000,000)                
Ending balance (in shares) at Oct. 31, 2022 69,255,675 69,255,675              
Ending balance at Oct. 31, 2022 $ 684,282,000 $ 69,000 2,159,957,000 (1,319,000) (3,791,000) (1,470,634,000)      
Beginning balance (in shares) at Apr. 30, 2022   68,061,063              
Beginning balance at Apr. 30, 2022 672,879,000 $ 68,000 1,945,737,000 (1,319,000) (4,679,000) (1,266,928,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock option exercises (in shares)   163,986              
Stock option exercises 1,332,000   1,332,000            
Vesting of restricted stock units (in shares)   388,483              
Vesting of restricted stock units 1,000 $ 1,000              
Stock-based compensation 96,554,000   96,554,000            
Conversion of 2024 convertible senior notes (in shares)   18              
Conversion of convertible senior notes 5,000   5,000            
Issuance of common stock under the Employee Stock Purchase Plan (in shares)   72,966              
Issuance of common stock under the Employee Stock Purchase Plan 15,777,000   15,777,000            
Unrealized income (loss) on available-for-sale securities 1,163,000       1,163,000        
Foreign currency translation adjustment (678,000)       (678,000)        
Net loss (118,865,000)         (118,865,000)      
Ending balance (in shares) at Jul. 31, 2022   68,686,516              
Ending balance at Jul. 31, 2022 668,168,000 $ 69,000 2,059,405,000 (1,319,000) (4,194,000) (1,385,793,000)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]                  
Stock option exercises (in shares)   199,043              
Stock option exercises 1,351,000   1,351,000            
Vesting of restricted stock units (in shares)   370,102              
Vesting of restricted stock units 0                
Stock-based compensation 99,198,000   99,198,000            
Conversion of 2024 convertible senior notes (in shares)   14              
Conversion of convertible senior notes 3,000   3,000            
Unrealized income (loss) on available-for-sale securities 1,139,000       1,139,000        
Foreign currency translation adjustment (736,000)       (736,000)        
Net loss $ (84,841,000)         (84,841,000)      
Ending balance (in shares) at Oct. 31, 2022 69,255,675 69,255,675              
Ending balance at Oct. 31, 2022 $ 684,282,000 $ 69,000 $ 2,159,957,000 $ (1,319,000) $ (3,791,000) $ (1,470,634,000)